| Income statement (USD) | Q2 2026 ended Jun 27, 2026 | Q1 2026 ended Mar 28, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 27, 2025 | Q2 2025 ended Jun 28, 2025 | Q1 2026 ended Mar 29, 2025 | Q4 2025 ended Dec 31, 2024 | Q3 2025 ended Sep 28, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.99B | 11.01B | 12.21B | 11.12B | 10.86B | 10.36B | 11.39B | 10.60B |
| Research and development | 364.00M | 336.00M | 356.00M | 346.00M | 352.00M | 342.00M | 374.00M | 346.00M |
| Selling, general and admin | 2.33B | 2.18B | 2.35B | 2.16B | 2.14B | 2.08B | 2.20B | 2.10B |
| Operating expenses | 9.91B | 9.14B | 9.96B | 9.18B | 9.02B | 8.65B | 9.38B | 8.76B |
| Operating income | 2.09B | 1.86B | 2.25B | 1.94B | 1.83B | 1.72B | 2.02B | 1.84B |
| EBITDA | 2.42B | 2.17B | 2.55B | 2.17B | 2.09B | 1.99B | 2.32B | 2.13B |
| Interest expense | 401.00M | 354.00M | 365.00M | 347.00M | 404.00M | 303.00M | 317.00M | 356.00M |
| Income before tax | 1.92B | 1.73B | 2.15B | 1.83B | 1.71B | 1.62B | 1.94B | 1.74B |
| Income tax | 167.00M | 70.00M | 153.00M | 207.00M | 92.00M | 95.00M | 150.00M | 99.00M |
| Net income | 1.74B | 1.65B | 1.98B | 1.62B | 1.62B | 1.51B | 1.83B | 1.63B |
| EPS | 4.68 | 4.44 | 5.22 | 4.28 | 4.28 | 3.99 | 4.79 | 4.26 |
| EPS (diluted) | 4.68 | 4.43 | 5.21 | 4.27 | 4.28 | 3.98 | 4.78 | 4.25 |
| Diluted shares | 371.00M | 373.00M | 0 | 378.00M | 378.00M | 379.00M | 0 | 384.00M |
| Dividends per share | 0.47 | 0.47 | 0.43 | 0.43 | 0.43 | 0.43 | 0.39 | 0.39 |
From Thermo Fisher Scientific's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.